NCT02364492View on ClinicalTrials.gov

A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2019

Study Completion Date

November 11, 2021

Conditions
Breast Neoplasms
Interventions
DRUG

MAG-TN3 + AS15

Trial Locations (5)

44805

Institut de Cancérologie de l'OUEST - Centre René Gauducheau, Nantes

75005

Institut Curie, Paris

94805

Institut Gustave Roussy (IGR), Villejuif

Unknown

Centre Léon Bérard, Lyon

HEGP, Paris

Sponsors

Lead Sponsor

Institut Pasteur
All Listed Sponsors
lead

Institut Pasteur

INDUSTRY

NCT02364492 - A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse | Biotech Hunter | Biotech Hunter